Miltefosine: issues to be addressed in the future.
Future issues that need to be addressed for miltefosine are efficacy against non-Indian visceral leishmaniasis, efficacy in HIV-coinfected patients, efficacy against the many forms of cutaneous and mucosal disease, effectiveness under clinical practice conditions, generation of drug resistance and the need to provide a second antileishmanial agent to protect against this disastrous event, and the ability to maintain reproductive contraceptive practices under routine clinical conditions.
Berman
J
J
bermanjo@mail.nih.gov
Bryceson
A D M
AD
Croft
S
S
Engel
J
J
Gutteridge
W
W
Karbwang
J
J
Sindermann
H
H
Soto
J
J
Sundar
S
S
Urbina
J A
JA
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D005544:Forecasting; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007896:Leishmaniasis / Q000150:complications / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine